Not exact matches
Still, he expects good
share -
price growth over the next few years, and if Europe's economic fortunes improve, then investors could see stocks soar.
When you purchase a broad swath of equities, say an S&P 500 index fund, the returns you can expect
over the next decade or so comprise four building blocks: the starting dividend yield, projected
growth in real earnings per
share, expected inflation, and the expected change in «valuation» — that is, the expansion or contraction in the
price / earnings (P / E) multiple.
If Netflix sees high revenue increases
over the next couple of years, based on strong subscriber
growth, customer retention, and low marketing spend, he predicts the
share price could reach $ 480.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain
growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market
share and
price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products
over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its
share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
But anyone hoping for the kind of stock
growth Shoppers enjoyed
over the past decade — when its
share price climbed from less than $ 18 to, at one point,
over $ 55 — will be disappointed.
Indeed, the strong
growth of investor housing loans has driven the
growth in household debt (as a
share of disposable incomes)
over recent years and contributed to a rise in both housing
prices and dwelling construction.
Any feedback into
prices is dampened by the low level of wage
growth, rebalancing of factor
shares, and a relatively low correlation that has developed
over time re the
price - wage relationship.
But even if America's future average economic
growth is as steep as optimists believe, say just
over 4 % a year, the current level of
share prices implies that profits will rise even faster.
Mac — in a declining PC industry, we expect Mac to continue its market
share gain and support our forecast for its strong performance of 7.3 % revenue
growth in FY 2015, followed by 3.6 % in FY 2016, and 4.6 % in FY 2017 on flat average selling
prices over the three year period of $ 1,230.
For example, an investor that ponders the probability that a company will report a certain earnings
growth rate
over a five - or ten - year period is much more apt to ride out short - term fluctuations in the
share price.
FedEx still offers an earnings
growth rate that is high for large companies, yet we were able to purchase
shares at
prices that were first seen in 2003, even though earnings per
share have more than doubled
over the period.
After all, assuming a constant
price - to - earnings multiple, a doubling in the
share price over a five - year period only requires earnings - per -
share to double, which translates to an annualized
growth rate of 14.9 %.
The current stock
price (~ $ 33 /
share) implies
over about 12 %
growth in profits compounded annually for about 10 years.
In a statement quoted by Barrons.com, the bank said that Treasury, which had seen its market
share in China grow
over the last three years, was
priced for «unrealistically high volume
growth in China, at peak
price points and peak margins».
But with the seemingly relentless
growth of Aldi (it now has more than 400 stores and a little
over 13 %
share in the grocery market, up about 3 % from when we last reported on supermarket
prices in 2015) there's a lot resting on the duopoly getting their
pricing strategy right.
$ 8 billion)
over first ten years for deficit reductionObeys PAYGO; Starting in 2026, 25 % of auction revenues for deficit reductionFuels and TransportationIncrease biofuels to 60 million gallons by 2030, low - carbon fuel standard of 10 % by 2010, 1 million plug» in hybrid cars by 2025, raise fuel economy standards, smart
growth funding, end oil subsidies, promote natural gas drilling, enhanced oil recoverySmart
growth funding, plug - in hybrids, raise fuel economy standards $ 7 billion a year for smart
growth funding, plug - in hybrids, natural gas vehicles, raise fuel economy standards; offshore drilling with revenue
sharing and oil spill veto, natural gas fracking disclosureCost ContainmentInternational offsetsOffset pool, banking and borrowing flexibility, soft
price collar using permit reserve auction at $ 28 per ton going to 60 % above three - year - average market
price» Hard»
price collar between $ 12 and $ 25 per ton, floor increases at 3 % + CPI, ceiling at 5 % + CPI, plus permit reserve auction, offsets like W - MClean Air Act And StatesNot discussedOnly polluters above 25,000 tons of carbon dioxide equivalent a year, regional cap and trade suspended until 2017, EPA to set stationary source performance standards in 2016, some Clean Air Act provisions excludedOnly polluters above 25,000 tons of carbon dioxide equivalent a year, regional cap and trade pre-empted, establishes coal - fired plant performance standards, some Clean Air Act provisions excludedInternational CompetitivenessTax incentives for domestic auto industryFree allowances for trade - exposed industries, 2020 carbon tariff on importsCarbon tariff on importsReferences: Barack Obama, 2007; Barack Obama, 8/3/08; Pew Center, 6/26/09; leaked drafts of American Power Act, 5/11/10.
Keegan Toci from BlackRock, Dave LaValle from State Street Global Advisors and Eric Pollackov from Invesco PowerShares
shared their insight and expertise as to what changes and improvements have been made
over the last few years to accommodate this
growth and ensure orderly
pricing, trading, and liquidity.
If the company recovers and increases exponentially
over the coming decades, those 7
shares will not participate in the
growth of the stock
price after the split event — you will only get the much lower cash - out amount for the
shares.
A quick look at the company's
share price over the past twelve months shows the
price has risen by 75 % but there's still more
growth to come.
Another of the high yield dividend aristocrats is KO which has seen solid dividend
growth and rising
share prices keeping yields in the 2 % to 3 % range
over the past decade.
To earn an annualized 5 % real return
over the next 10 years with a 2 % dividend yield, we'll need 3 % real
share -
price growth.
Oddly enough, it's value investors who often skip this step... maybe because they're too busy drooling
over what they see as a free lunch — i.e. an obvious & substantial
share price discount to a stock's intrinsic value, something you're far less likely to see up - front with a
growth stock.
Share Repurchases: Let's assume the DCP share price increases by just over 40 % in the next year & continues at half that growth rate (just over 20 % pa) for the following 4 y
Share Repurchases: Let's assume the DCP
share price increases by just over 40 % in the next year & continues at half that growth rate (just over 20 % pa) for the following 4 y
share price increases by just
over 40 % in the next year & continues at half that
growth rate (just
over 20 % pa) for the following 4 years.
But rather than avoid the US, or agonise
over the timing of a potential buy, I think it presents the ideal opportunity to slowly but surely average into high quality US
growth stocks which have already (and / or perhaps will still) suffer a temporary
share price / valuation setback.
Smaller high -
growth companies tend to outperform their larger peers
over the long - term and hugely successful ones are referred to as the five or ten — baggers which is the term used to describe stocks which have increased five to ten times in
share price over a length of time, usually three, five or ten years.
Now, sure, I could map out a «precise»
growth trajectory for Alphabet
over the next five years & a future / target
share price, but that just offers up a hostage to fortune... And anyway, anybody who wants to buy the
shares needs to ponder this trajectory for themselves.
From anger
over rising energy
prices to a continued
growth of peer - to - peer
sharing and collaborative consumption, there was plenty of familiar territory for TreeHugger readers.
Sending a clear signal to the States that the previous Government's cooperative agenda on health is
over, the Treasurer announced that the Commonwealth will walk away from its commitment to
share equally in
growth hospital funding, indexing funding to a combination of
growth in the consumer
price index and population, from 2017 - 18.
Over the past year, continued home
price growth has helped spur a sizable increase in the net
share of consumers who say it's a good time to sell a home, but also a modest weakening in the net
share who say it is a good time to buy.»
«The strategy to go offshore paid off and has given our funds and SA investors rand hedge exposure (NEPI has shown
over 12 % pa
growth in Euros every year since listing) while the size and liquidity matter, and the inclusion into local and foreign Indexes give the
shares a huge
growth in
price and brought in new investors.